News | January 22, 2025
Sunshine Biopharma launches Olanzapine and Olanzapine ODT
Olanzapine is indicated for the acute and maintenance treatment of schizophrenia and related psychotic disorders
Olanzapine is indicated for the acute and maintenance treatment of schizophrenia and related psychotic disorders
The project will provide additional support for late-stage development and licensure of pre-pandemic mRNA-based vaccines
Based on ECHO Phase III trial results which showed more than 16 months of progression-free survival improvement vs. chemoimmunotherapy alone
Lonza to develop spray-dried formulations for an intranasally-delivered biologic for Iconovo at its Center of Excellence for bioavailability enhancement and inhaled delivery in Bend (US)
The project is set to attract significant manufacturing investments of approximately Rs. 10,500 crore and is also projected to create around 1 lakh direct and indirect jobs
He also laid the foundation stone for a state-of-the-art 50-bedded Critical Care Block (CCB)
Increases speed to market for drug developers working on nucleic acid therapeutics
India's bio economy has experienced remarkable growth, skyrocketing from $10 billion in 2014 to over $130 billion in 2024, with projections to reach $300 billion by 2030
Expects to unlock further opportunities in the Moldovan market, contributing anticipated sales of $300,000 in 2025 and approximately $700,000–$800,000 in 2026
Exclusive global license outside of Greater China for SHR-4849, a Phase 1 DLL3-targeting Topo-I-payload antibody drug conjugate (ADC)
Subscribe To Our Newsletter & Stay Updated
